Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression
Thomas E. Stinchcombe, Rebecca A. Miksad, Anala Gossai, Sandra D. Griffith, Aracelis Z. Torres
Topics & Concepts
MedicineAtezolizumabNivolumabPembrolizumabInternal medicineHazard ratioLung cancerProportional hazards modelLog-rank testRetrospective cohort studyOncologyCancerImmunotherapyConfidence intervalCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies